ISCO · XBRL financial data

International Stem Cell financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ISCO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	1,973	1,889*	2,129	2,331	2,179	2,446*	2,129	2,447	2,369	2,155*	2,315	2,675
Cost of revenue	781	863*	887	913	974	990*	992	927	1,048	1,066*	954	1,217
Research and development	155	166*	177	83	187	210*	187	162	158	177*	156	155
General and administrative	832	964*	909	884	816	907*	892	905	789	946*	1,122	1,062
Operating income (loss)	(97)	(424)*	(178)	149	(90)	51*	(215)	167	94	(313)*	(190)	(35)
Interest expense	34	34*	36	35	35	39*	41	38	37	35*	35	34
Other income (expense)	0*	0*	—	5	0*	(1)*	—	—	—	—	5	(2)
Income tax expense (benefit)	—	—	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(131)	(458)*	(214)	119	(125)	11*	(256)	129	57	(348)*	(220)	(71)
Earnings per share, basic USD per share	(0.02)	(0.06)*	(0.03)	0.01	(0.02)	0.00*	(0.03)	0.01	0.00	(0.04)*	(0.03)	(0.01)
Earnings per share, diluted USD per share	(0.02)	(0.06)*	(0.03)	0.01	(0.02)	0.00*	(0.03)	0.01	0.00	(0.04)*	(0.03)	(0.01)
Weighted average shares, basic thousands of shares	8,004	8,005*	8,004	8,004	8,004	8,004*	8,004	8,004	8,004	8,004*	8,004	8,004
Weighted average shares, diluted thousands of shares	8,004	8,005*	8,004	8,004	8,004	8,004*	8,004	8,004	8,167	7,841*	8,004	8,004

Balance sheet

CSV

Fiscal quarters (ISCO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	1,430	1,588	1,386	1,290	1,307	1,230	1,452	920	966	993	933	1,089
Accounts receivable	644	574	632	810	680	1,058	851	1,101	1,015	723	791	959
Inventory	1,317	1,263	1,273	1,415	1,384	1,149	1,258	1,550	1,591	1,514	1,773	1,685
Prepaid and other current assets	267	96	302	304	119	123	277	269	162	181	316	187
Total current assets	3,658	3,521	3,593	3,819	3,490	3,560	3,838	3,840	3,734	3,411	3,813	3,920
Property and equipment, net	243	215	196	286	290	257	227	225	192	160	169	159
Right-of-use asset	603	557	510	460	407	352	587	504	425	344	261	175
Total assets	5,641	5,390	5,369	5,594	5,180	5,173	5,624	5,547	5,282	4,819	5,133	5,056
Accounts payable	303	364	360	377	321	186	457	397	265	168	437	310
Accrued liabilities	442	485	578	572	475	527	608	651	452	428	842	969
Total current liabilities	4,682	4,832	4,966	5,024	4,718	4,688	5,108	4,939	4,655	4,579	5,049	4,984
Lease liability, non-current	518	445	367	286	203	115	302	204	103	0	0	0
Total liabilities	5,200	5,277	5,333	5,310	4,921	4,803	5,410	5,143	4,758	4,579	5,049	4,984
Accumulated deficit	(110,018)	(110,476)	(110,690)	(110,571)	(110,696)	(110,685)	(110,941)	(110,812)	(110,755)	(111,103)	(111,323)	(111,394)
Total stockholders' equity	(3,859)	(4,187)	(4,264)	(4,016)	(4,041)	(3,930)	(4,086)	(3,896)	(3,776)	(4,060)	(4,216)	(4,228)
Total liabilities and equity	5,641	5,390	5,369	5,594	5,180	5,173	5,624	5,547	5,282	4,819	5,133	5,056
Common shares outstanding (cover page) thousands of shares	8,004	8,004	8,004	8,004	8,004	8,004	8,004	8,004	8,004	8,004	8,004	8,004

Cash flows

CSV

Fiscal quarters (ISCO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(131)	(458)*	(214)	119	(125)	11*	(256)	129	57	(348)*	(220)	(71)
Stock-based compensation	118*	130*	137	129	100	100*	100	61	63	64*	64	59
Depreciation and amortization	47*	48*	49	50	53	54*	55	54	56	54*	34	28
Net cash from operating activities	62*	161*	(193)	23*	257*	(74)*	227	(300)*	49*	32*	121	167*
Purchases of property and equipment	14*	0*	8	120*	37*	1*	5	32*	3*	3*	23	7*
Net cash from investing activities	(14)*	(3)*	(9)	(119)*	(40)*	(3)*	(5)	(32)*	(3)*	(5)*	(31)	(11)*
Net cash from financing activities	—	—	—	—	—	0*	—	—	0*	0*	(150)	0*
Net change in cash	48*	158*	(202)	(96)*	17*	(77)*	222	(532)*	46*	27*	(60)	156*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
International Stem Cell	1,089	2,675	167*	8.0M	—	Q2 FY26 10-QJun 30, 2026
Emmaus Life Sciences	2,808	6,318	1,693*	70.2M	—	Q2 FY26 10-QJun 30, 2026
Avenue Therapeutics	1,942	0	(475)*	3.3M	4.1 quarters	Q2 FY26 10-QJun 30, 2026
Nutra Pharma	not reported	34	(251)*	7.2B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Mosaic ImmunoEngineering	0	not reported	(0)*	7.2M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
China Foods Holdings	16	0	(94)*	20.3M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Hepion Pharmaceuticals	1,629	not reported	(1,394)*	90.2M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Evoke Pharma	11,576	4,284	(522)*	1.7M	22.2 quarters	Q3 FY25 10-QSep 30, 2025
Twinlab Consolidated Holdings	13	not reported	(907)*	259.1M	0.0 quarters	Q4 FY24 10-KDec 31, 2024

Not investment advice. Not affiliated with the U.S. SEC.